×
About 26,894 results

ALLMedicine™ Chronic Lymphocytic Leukemia Center

Research & Reviews  12,111 results

ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lympho...
https://doi.org/10.1182/blood.2020009960
Blood Chen J, Sathiaseelan V et. al.

Feb 23rd, 2021 - The expression of ZAP-70 in a subset of CLL patients strongly correlates with a more aggressive clinical course, though the exact underlying mechanisms remain elusive. The ability of ZAP-70 to enhance B cell receptor (BCR) signaling, independently...

Chronic Lymphocytic Leukemia Presenting as Scleral Nodule.
https://doi.org/10.1016/j.ophtha.2020.09.037
Ophthalmology Vahdani K, Thaung C et. al.

Feb 22nd, 2021 - Chronic Lymphocytic Leukemia Presenting as Scleral Nodule.|2021|Vahdani K,Thaung C,Rose GE,|

Reduced expansion of CD94/NKG2C+ NK cells in chronic lymphocytic leukemia and CLL-like ...
https://doi.org/10.1111/ijlh.13494
International Journal of Laboratory Hematology; Puiggros A, Blanco G et. al.

Feb 22nd, 2021 - Dysregulated NK cell-mediated immune responses contribute to tumor evasion in chronic lymphocytic leukemia (CLL), although the NK cell compartment in CLL-like monoclonal B-cell lymphocytosis (MBL) is poorly understood. In healthy individuals, huma...

Randomized controlled trial of individualized, low dose, fixed duration lenalidomide ma...
https://doi.org/10.1080/10428194.2021.1885668
Leukemia & Lymphoma; Jindal N, Lad DP et. al.

Feb 22nd, 2021 - Lenalidomide maintenance after frontline chemo-immunotherapy (CIT) in chronic lymphocytic leukemia (CLL) has not been standard due to the availability of novel therapies, though these remain out of reach for most in low-middle income countries. Th...

Eosinophilic folliculitis, eosinophilic dermatosis of hematologic malignancy and acneif...
https://doi.org/10.1111/cup.13932
Journal of Cutaneous Pathology; Bailey CAR, Laurain DA et. al.

Feb 22nd, 2021 - Within the literature, there is overlap in the histopathological features described in eosinophilic folliculitis associated with chronic lymphocytic leukemia (CLL), eosinophilic dermatosis of hematologic malignancy, and acneiform follicular mucino...

see more →

Guidelines  49 results

Addition of Ublituximab to Ibrutinib Appears Safe and Effective for Patients With High-Risk Chronic Lymphocytic Leukemia
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200124/full/

May 12th, 2020 - Although chronic lymphocytic leukemia (CLL) has a relatively high 5-year survival rate (85% for people age 20 and older), effective treatments for advanced disease are still needed. Use of combination or monotherapy Bruton’s tyrosine kinase (BTK) ...

Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192083/
Leukemia Research; Paneesha S

Apr 29th, 2020 - The global pandemic of the novel coronavirus SARS-CoV-2 represents one of the greatest infectious challenges to human health in recent history. At the current time over 3.2 million people have been infected and this has proved fatal in over 230,00...

FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ibrutinib-plus-rituximab-chronic-lymphocytic-leukemia
FDA

Apr 20th, 2020 - The Food and Drug Administration expanded the indication of ibrutinib (IMBRUVICA, Pharmacyclics LLC) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic...

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical ...
https://doi.org/10.6004/jnccn.2020.0006
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.

Feb 5th, 2020 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in...

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology
https://jnccn.org/view/journals/jnccn/18/2/article-p185.xml
JNCCN Wierda WG,et al

Dec 31st, 2019 - Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are characterized by a progressive accumulation of leukemic cells in the peripheral blood, bone marrow, and lymphoid tissues. Treatment of CLL/SLL has evolved significantly in...

see more →

Drugs  77 results see all →

Clinicaltrials.gov  13,293 results

Treatment With LOXO-305 Results in Durable Efficacy in Heavily Pretreated Patients With CLL/SLL
https://ascopost.com/issues/february-25-2021-supplement-conference-highlights-ash-2020/treatment-with-loxo-305-results-in-durable-efficacy-in-heavily-pretreated-patients-with-cllsll/

Feb 24th, 2021 - Despite the marked efficacy of ibrutinib, acalabrutinib, and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), treatment failure can occur through the development of resistance. In addition, patients in whom Bruton’s...

ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lympho...
https://doi.org/10.1182/blood.2020009960
Blood Chen J, Sathiaseelan V et. al.

Feb 23rd, 2021 - The expression of ZAP-70 in a subset of CLL patients strongly correlates with a more aggressive clinical course, though the exact underlying mechanisms remain elusive. The ability of ZAP-70 to enhance B cell receptor (BCR) signaling, independently...

Chronic Lymphocytic Leukemia Presenting as Scleral Nodule.
https://doi.org/10.1016/j.ophtha.2020.09.037
Ophthalmology Vahdani K, Thaung C et. al.

Feb 22nd, 2021 - Chronic Lymphocytic Leukemia Presenting as Scleral Nodule.|2021|Vahdani K,Thaung C,Rose GE,|

Reduced expansion of CD94/NKG2C+ NK cells in chronic lymphocytic leukemia and CLL-like ...
https://doi.org/10.1111/ijlh.13494
International Journal of Laboratory Hematology; Puiggros A, Blanco G et. al.

Feb 22nd, 2021 - Dysregulated NK cell-mediated immune responses contribute to tumor evasion in chronic lymphocytic leukemia (CLL), although the NK cell compartment in CLL-like monoclonal B-cell lymphocytosis (MBL) is poorly understood. In healthy individuals, huma...

Randomized controlled trial of individualized, low dose, fixed duration lenalidomide ma...
https://doi.org/10.1080/10428194.2021.1885668
Leukemia & Lymphoma; Jindal N, Lad DP et. al.

Feb 22nd, 2021 - Lenalidomide maintenance after frontline chemo-immunotherapy (CIT) in chronic lymphocytic leukemia (CLL) has not been standard due to the availability of novel therapies, though these remain out of reach for most in low-middle income countries. Th...

see more →

News  1,349 results

Experts Offer Roadmap for Treating CLL During the Pandemic
https://www.medscape.com/viewarticle/943140

Dec 22nd, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. COVID-19 has thrown a wrench in standard treatment protocols for patients with chronic lymphocytic leukemia (CLL). These patients already face a g...

Fixed Duration Ibrutinib/Venetoclax Feasible for Some CLL/SLL
https://www.medscape.com/viewarticle/942191

Dec 7th, 2020 - Among chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients in the minimal residual disease (MRD) cohort of the phase 2 CAPTIVATE trial, a 1-year disease-free survival (DFS) rate of 95% in those randomized to placebo after 1...

Pigment Traits, Sun Sensitivity Tied to Risk for Blood Cancers
https://www.medscape.com/viewarticle/941593

Nov 24th, 2020 - Risk factors for keratinocyte carcinomas, primarily pigment traits and sun sensitivity, were associated with the risk of developing non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL) in an analysis of 92,097 women in France. The pr...

Meta-Analysis: Acalabrutinib Bests Other Frontline CLL Therapies
https://www.staging.medscape.com/viewarticle/938885

Oct 8th, 2020 - Acalabrutinib, given alone or in combination with obinutuzumab, showed favorable progression-free survival (PFS) and overall survival (OS), compared with other frontline therapies for chronic lymphocytic leukemia (CLL) in fludarabine-ineligible pa...

Meta-Analysis: Acalabrutinib Bests Other Frontline CLL Therapies
https://www.medscape.com/viewarticle/938885

Oct 8th, 2020 - Acalabrutinib, given alone or in combination with obinutuzumab, showed favorable progression-free survival (PFS) and overall survival (OS), compared with other frontline therapies for chronic lymphocytic leukemia (CLL) in fludarabine-ineligible pa...

see more →

Patient Education  15 results see all →